2.2 and 2.7 Å resolution data sets were collected from crystals of the human apurinic/apyrimidinic endonuclease 1 (APE1) truncated of the first 61 N-terminal residues in the presence of a 15-mer DNA containing an oxidatively damaged base as the target base. For both complexes, APE1 crystallized with a 6-mer DNA, suggesting that nucleotide incision and 3′→5′ exonuclease reactions occurred prior to crystallization.
Keywords: human endonuclease 1, APE1, oxidatively damaged bases, base-excision repair, nucleotide-incision repair
Abstract
The multifunctional human apurinic/apyrimidinic (AP) endonuclease 1 (APE1) is a key enzyme involved in both the base-excision repair (BER) and nucleotide-incision repair (NIR) pathways. In the NIR pathway, APE1 incises DNA 5′ to a number of oxidatively damaged bases. APE1 was crystallized in the presence of a 15-mer DNA containing an oxidatively damaged base in a single central 5,6-dihydrouracil (DHU)·T or α-anomeric 2′-deoxyadenosine (αdA)·T base pair. Diffraction data sets were collected to 2.2 and 2.7 Å resolution from DNA-DHU–APE1 and DNA-αdA–APE1 crystals, respectively. The crystals were isomorphous and contained one enzyme molecule in the asymmetric unit. Molecular replacement was performed and the initial electron-density maps revealed that in both complexes APE1 had crystallized with a degradation DNA product reduced to a 6-mer, suggesting that NIR and exonuclease reactions occurred prior to crystallization.
1. Introduction
Aerobic respiration and exogenous factors such as ionizing radiation and drugs generate reactive oxygen species (ROS) such as
, H2O2,
and
. DNA has limited chemical stability and is one of the most biologically important targets of ROS (Cadet et al., 2003 ▶). Oxidative DNA lesions are believed to be a major type of endogenous damage and their accumulation contributes to human degenerative disorders, including cancer, cardiovascular disease and brain dysfunction. The major human apurinic/apyrimidinic (AP) endonuclease (APE1) is a key protein in the repair of oxidative damage to DNA and RNA (Evans et al., 2000 ▶; Tell et al., 2010 ▶). APE1 participates in both the base-excision repair (BER) and nucleotide-incision repair (NIR) pathways. In the BER pathway, APE1 cleaves DNA at AP sites and 3′-blocking moieties generated by DNA glycosylases (Hitomi et al., 2007 ▶). Alternatively, in the NIR pathway APE1 incises 5′ to a damaged base in a DNA glycosylase-independent manner, providing 3′-hydroxy ends for DNA synthesis, coupled with the repair of the remaining 5′-dangling modified nucleotide (Ischenko & Saparbaev, 2002 ▶; Gros et al., 2004 ▶). APE1 incises DNA containing 5,6-dihydrouracil (DHU) and α-anomeric 2′-deoxyadenosine (αdA) residues, which constitute the major DNA adducts generated by ionizing radiation under anoxic conditions (Jorgensen et al., 1988 ▶; Lesiak & Wheeler, 1990 ▶; Dizdaroglu et al., 1993 ▶). APE1 also possesses a 3′→5′ exonuclease activity which removes 3′-mismatches and oxidized nucleotides (Chou & Cheng, 2002 ▶; Parsons et al., 2005 ▶) and an endonuclease activity on undamaged DNA which is involved in DNA fragmentation during apoptosis (Yoshida et al., 2003 ▶). Interestingly, the NIR and 3′→5′ exonuclease functions of APE1 are genetically linked and are governed by the same amino-acid residues (Daviet et al., 2007 ▶; Golan et al., 2010 ▶). Previously, we have demonstrated that NIR is a distinct and separable function of AP endonucleases that is essential for handling lethal oxidative DNA lesions which cannot be removed in the BER pathway (Ishchenko et al., 2006 ▶).
X-ray structures of apo APE1 have been determined (PDB codes 1bix, 1hd7 and 1e9n; Gorman et al., 1997 ▶; Beernink et al., 2001 ▶) and that of APE1 bound to DNA containing a synthetic AP site showed that the enzyme binds to a flipped-out abasic deoxyribose moiety in a pocket that excludes normal DNA nucleotides (Mol et al., 2000 ▶). Together with our previous biochemical characterization, these structural data suggest that APE1 may exist in at least two alternative BER-proficient and NIR/exonuclease-proficient conformations in order to accommodate both an abasic site and a damaged base within its active-site pocket.
In order to understand the structural basis of the recognition of a damaged DNA base by an AP endonuclease, we initiated the crystallographic study of APE1 in complex with a DNA fragment containing an oxidatively damaged base as a target base. APE1 was overproduced and purified in an N-terminally truncated form (ΔN61-APE1) since its N-terminal region is known to be highly flexible. Here, we report the crystallization and preliminary X-ray analysis of APE1 in the presence of a DNA fragment containing a damaged base.
2. DNA preparation
The sequence of the 15-mer DNA used for crystallization assays was d(CTGCATAXGCATGTA)·d(TACATGCTTATGCAG), where X is a damaged base (DHU or αdA). The oligonucleotides were purchased from Eurogentec (Seraing, Belgium) and hybridized by mixing equal concentrations (10 mM) in 2 mM Tris–HCl pH 7.0 heated to 338 K for 3 min and cooled to room temperature over 2 h. The MALDI–TOF mass-spectrometric analysis of the oligonucleotides performed by the manufacturer validated their size and homogeneity (data not shown). In addition, the purity and integrity of the oligonucleotide preparations were verified by denaturing PAGE (data not shown).
3. Crystallization
ΔN61-APE1 (lacking the first 61 residues) was purified as described by Daviet et al. (2007 ▶). In crystallization trials, the DNA duplexes were mixed with ΔN61-APE1 protein at a concentration of 7.5 mg ml−1 in a buffer consisting of 20 mM HEPES pH 7.5 and 130 mM KCl in a 2:1 stoichiometry. Commercial crystallization kits (the PEGs II, Classics and MbClass suites from Qiagen) were screened in sitting-drop vapour-diffusion experiments using a nanodrop robot (Cartesian Proteomic Solutions) and 200 nl drops at 293 K. Small crystals appeared within one to two weeks in Classics condition F4 [0.1 M HEPES pH 7.5, 10%(m/v) PEG 8000] and MbClass condition F9 [0.05 M sodium phosphate pH 6.8, 12%(m/v) PEG 4000] for DNA duplexes containing a DHU and an αdA base, respectively (Fig. 1 ▶).
Figure 1.
Crystals of DNA-DHU–APE1 (a) and DNA-αdA-APE1 (b) (the scale bar is labelled in mm).
4. Data collection and processing
Small crystals were flash-cooled in a cryoprotecting solution consisting of the mother solution supplemented with 25%(v/v) glycerol. Data-collection experiments were carried out at 100 K on the PROXIMA 1 beamline at SOLEIL (Saint Aubin, France). 150° and 96° of data were collected in 1° frames with 1 s exposure per frame for the DNA-DHU–APE1 and DNA-αdA–APE1 crystals, respectively (Fig. 2 ▶). Diffraction intensities were evaluated with the program XDS (Kabsch, 2010 ▶) to resolutions of 2.2 and 2.7 Å, respectively, and were further processed using the CCP4 program suite (Collaborative Computational Project, Number 4, 1994 ▶). The crystals of both complexes belonged to the same orthorhombic space group, P21212, and are isomorphous. Data-collection and processing statistics are given in Table 1 ▶.
Figure 2.
Diffraction pattern of the DNA-DHU–APE1 crystal. (a) The outer resolution shell is 2.2 Å (1.7 Å at the edge of the detector). (b) Enlarged view of the region marked by a rectangle in (a).
Table 1. Data-collection statistics.
Values in parentheses are for the highest resolution shell (of nine).
| DNA-DHU–APE1 | DNA-αdA–APE1 | |
|---|---|---|
| Space group | P21212 | P21212 |
| Unit-cell parameters (Å) | a = 105.3, b = 44.9, c = 72.4 | a = 106.2, b = 45.1, c = 72.6 |
| Resolution (Å) | 30.0–2.20 (2.32–2.20) | 30.0–2.70 (2.85–2.70) |
| No. of observed reflections | 65369 | 50675 |
| No. of unique reflections | 16482 | 9659 |
| Completeness (%) | 97.6 (97.5) | 95.9 (88.0) |
| Rmerge† (%) | 9.3 (40.8) | 9.9 (51.2) |
| I/σ(I) | 6.2 (2.0) | 6.8 (2.0) |
R
merge =
, where I
i(hkl) is the ith observed amplitude of reflection hkl and 〈I(hkl)〉 is the mean amplitude for all observations i of reflection hkl.
5. Molecular replacement
The asymmetric unit can only contain one ΔN61-APE1–DNA complex, corresponding to a Matthews coefficient (Matthews, 1968 ▶) of 2.26 Å3 Da−1 and a solvent content of 45.7%. Molecular replacement using the program Phaser (Storoni et al., 2004 ▶) and the structure of apo APE1 (PDB code 1bix) without the first 61 residues as a search model led to a solution with good scores (RFZ = 18.7 and 17.3, TFZ = 34.5 and 31.5, LLG = 2347 and 1705 for the DNA-DHU–APE1 and DNA-αdA–APE1 crystals, respectively) and an initial R factor of 31%. Examination of the resulting model and density maps for both complexes clearly showed that APE1 crystallized with a degraded DNA fragment that was subsequently identified as a 6-mer. One end of the 6-mer enters the active site of APE1, while the opposite end stacks end-to-end in the crystal, forming a pseudo-continuous 12-mer. Refinement of these two APE1 structures in complex with a 6-mer DNA, including attribution of the DNA sequence, is under way.
Acknowledgments
We are grateful to Andrew Thompson for help in data collection on PROXIMA 1. This work was supported by grants from the Russian Ministry of Education and Science state contract 02.740.11.5012 (to AAI) and MK-1304.2010.4 (to NAK) and from the CNRS GDRE 182, Fondation pour la Recherche Médicale ‘EQUIPES FRM 2007’ and Electricité de France Contrat Radioprotection RB 2010 (to MS). The crystallization work benefited from the LEBS facilities of the IMAGIF Structural Biology and Proteomic Unit at the Gif campus (http://www.imagif.cnrs.fr).
References
- Beernink, P. T., Segelke, B. W., Hadi, M. Z., Erzberger, J. P., Wilson, D. M. III & Rupp, B. (2001). J. Mol. Biol.307, 1023–1034. [DOI] [PubMed]
- Cadet, J., Douki, T., Gasparutto, D. & Ravanat, J. L. (2003). Mutat. Res.531, 5–23. [DOI] [PubMed]
- Chou, K.-M. & Cheng, Y.-C. (2002). Nature (London), 415, 655–659. [DOI] [PubMed]
- Collaborative Computational Project, Number 4 (1994). Acta Cryst. D50, 760–763.
- Daviet, S., Couve-Privat, S., Gros, L., Shinozuka, K., Ide, H., Saparbaev, M. & Ishchenko, A. A. (2007). DNA Repair, 6, 8–18. [DOI] [PubMed]
- Dizdaroglu, M., Laval, J. & Boiteux, S. (1993). Biochemistry, 32, 12105–12111. [DOI] [PubMed]
- Evans, A. R., Limp-Foster, M. & Kelley, M. R. (2000). Mutat. Res.461, 83–108. [DOI] [PubMed]
- Golan, G., Ishchenko, A. A., Khassenov, B., Shoham, G. & Saparbaev, M. K. (2010). Mutat. Res.685, 70–79. [DOI] [PubMed]
- Gorman, M. A., Morera, S., Rothwell, D. G., de La Fortelle, E., Mol, C. D., Tainer, J. A., Hickson, I. D. & Freemont, P. S. (1997). EMBO J.16, 6548–6558. [DOI] [PMC free article] [PubMed]
- Gros, L., Ishchenko, A. A., Ide, H., Elder, R. H. & Saparbaev, M. K. (2004). Nucleic Acids Res.32, 73–81. [DOI] [PMC free article] [PubMed]
- Hitomi, K., Iwai, S. & Tainer, J. A. (2007). DNA Repair, 6, 410–428. [DOI] [PubMed]
- Ishchenko, A. A., Deprez, E., Maksimenko, A., Brochon, J. C., Tauc, P. & Saparbaev, M. K. (2006). Proc. Natl Acad. Sci. USA, 103, 2564–2569. [DOI] [PMC free article] [PubMed]
- Ischenko, A. A. & Saparbaev, M. K. (2002). Nature (London), 415, 183–187. [DOI] [PubMed]
- Jorgensen, T. J., Furlong, E. A. & Henner, W. D. (1988). Radiat. Res.114, 556–566. [PubMed]
- Kabsch, W. (2010). Acta Cryst. D66, 125–132. [DOI] [PMC free article] [PubMed]
- Lesiak, K. B. & Wheeler, K. T. (1990). Radiat. Res.121, 328–337. [PubMed]
- Matthews, B. W. (1968). J. Mol. Biol.33, 491–497. [DOI] [PubMed]
- Mol, C. D., Izumi, T., Mitra, S. & Tainer, J. A. (2000). Nature (London), 403, 451–456. [DOI] [PubMed]
- Parsons, J. L., Dianova, I. I. & Dianov, G. L. (2005). Nucleic Acids Res.33, 2204–2209. [DOI] [PMC free article] [PubMed]
- Storoni, L. C., McCoy, A. J. & Read, R. J. (2004). Acta Cryst. D60, 432–438. [DOI] [PubMed]
- Tell, G., Wilson, D. M. III & Lee, C. H. (2010). Mol. Cell. Biol.30, 366–371. [DOI] [PMC free article] [PubMed]
- Yoshida, A., Urasaki, Y., Waltham, M., Bergman, A. C., Pourquier, P., Rothwell, D. G., Inuzuka, M., Weinstein, J. N., Ueda, T., Appella, E., Hickson, I. D. & Pommier, Y. (2003). J. Biol. Chem.278, 37768–37776. [DOI] [PubMed]


